Incyte Halts Jakafi Colorectal Cancer Trial
This article was originally published in Scrip
Executive Summary
Incyte Corporation has suspended development of its Janus-associated kinase (JAK) inhibitor, Jakafi (ruxolitinib), in colorectal cancer after a Phase II study failed to show sufficient efficacy, but analysts say the indication is more desirable than crucial to the product's market success.